Black Diamond Therapeutics Inc (BDTX)

[dcaf7]

Titles of silevertinib presentations at ASCO 2026 are posted:
1. Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations. Rapid Oral Abstract Session, May 30, 2026.
2. Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations. Poster Session, May 31, 2026.
3. Randomized phase 2 study to evaluate the efficacy and safety of silevertinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastoma. Poster Session, Jun 1, 2026. This is TPS presentation, only about trial design, don't expect any clinical data.
The full, final text of these abstracts will be available on May 21 at 05:00 PM EST. I suspect that the first and possibly second abstracts are placeholders, with final data to be disclosed during the presentations.